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Cyclic AMP-stimulated mRNA levels in cultured rat hepatocytes were inhibited by three different inhibitors of CAMP- 
dependent protein kinase activity: (i) Rp-CAMPS, a CAMP analog with a sulfur substitution at the equatorial oxygen 
of the cyclic monophosphate; (ii) H8, an isoquinoline sulfonamide derivative; and (iii) PKI, a 20-amino acid synthetic 
peptide of the Walsh protein kinase inhibitor. These inhibitors specifically blocked the CAMP-stimulated increase in 
mRNA for tyrosine aminotransferase and phosphoenolpyruvate carboxykinase; they had no effect on the level of albumin 
mRNA which is not CAMP regulated. These results provide functional evidence that kinase activity involving protein 
phosphorylation is required in CAMP-mediated gene expression in mammalian cells. 
Protein kinase subunit inhibitor; cyclic AMP-stimulated transcription; Tyrosine aminotransferase; Phosphoenolpyruvate carboxykinase; 
(Hepatocyte) 
1. INTRODUCTION 
CAMP-regulated gene expression has been 
demonstrated both in procaryotic and eucaryotic 
cells, however, the mediators of CAMP action in 
these cell types are strikingly different. In E. cob 
CAMP binds to a CAMP receptor protein (CRP or 
CAP) and activates the expression of a series of 
genes for enzymes of sugar catabolism [l]. 
Eucaryotic cells contain an analogous CAMP 
receptor protein which has amino acid homologies 
to CRP, that is, the regulatory subunit (R) of 
CAMP-dependent protein kinase (CAMP-PK) [2]. 
The protein kinase however also consists of a 
catalytic subunit (C) which is the prime mediator 
of most CAMP actions in eucaryotes [3]. Never- 
theless, it has been recently reported that in the 
lower eucaryote Dictyostelium discoideum a cell 
surface receptor for CAMP, not protein kinase, 
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mediates gene expression [4,5]. Cell surface R has 
been reported in mammalian cells, and R has been 
shown to be associated with both soluble and 
membrane fractions, as well as associated with in- 
tracellular structures including the cytoskeleton in 
the area of microtubules and Golgi [6-81. In addi- 
tion, there are at least three distinct types of R 
subunits which are products of different genes 
[9, lo]. The greater complexity of the CAMP 
mediator in mammalian cells has necessitated the 
investigation of whether the regulatory or catalytic 
subunit of CAMP-PK is essential for the 
mechanism of CAMP-regulated gene expression in 
these cells. CAMP increases mRNA synthesis for a 
number of mammalian proteins [11,12] including 
two in liver, tyrosine aminotransferase (TAT) 
[ 13,141 and phosphoenolpyruvate carboxykinase 
(PEPCK) [15], which were examined here. The 
results indicate that protein phosphorylation by 
the catalytic subunit is required for CAMP stimula- 
tion of mRNA for these enzymes. These data have 
been. presented in abstract form [16]. 
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2. MATERIALS AND METHODS 
2.1. Kinase activators and inhibitors (structures in fig.1) 
Activators of CAMP-dependent protein kinase used were 
8-chlorophenylthio-CAMP (8CPT-CAMP) and Sp-CAMPS, a 
CAMP analog with a sulfur substitution at the axial oxygen of 
the cyclic monophosphate. 8CPT-CAMP was used in most ex- 
periments ince its properties are superior to CAMP for studies 
on intact cells, i.e., it is more lipophilic [17] and more resistant 
to hydrolysis by phosphodiesterase [18]. These properties also 
apply to the agonist Sp-CAMPS which was used in experiments 
in which the antagonist Rp-CAMPS was examined. Sp-CAMPS 
has a lower affinity than SCPT-CAMP for CAMP-PK [19] and 
can be more readily competed against by Rp-CAMPS [20]. Rp- 
CAMPS is an inhibitor of both type I and type II CAMP-PK in 
vitro and in vivo [19], is slightly more lipophilic than CAMP 
[17], at high concentrations can inhibit CAMP and cGMP 
hydrolysis by phosphodiesterase [21] and is itself not hydro- 
lyzed by any mammalian phosphodiesterase o far tested [18]. 
The effectiveness of Rp-CAMPS as a CAMP-PK antagonist in 
intact hepatocytes has been demonstrated [20]. 
Rp-CAMPS inhibits CAMP-PK by preventing holoenzyme 
dissociation, whereas two other inhibitors, used directly, inhibit 
kinase free C activity. H8, an isoquinoline derivative which 
mimics the adenine of ATP, inhibits CAMP-PK, as well as other 
protein kinases, to various extents [22]. Two other inhibitors, 
each 20-amino acid synthetic peptides representing the active 
domain of the Walsh protein kinase inhibitor (PKI) which acts 
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Fig.1. Structures of kinase activators and inhibitors. The 
CAMP-PK substrate recognition site is underlined in Kemptide. 
PKI-1 and PKI-2 inhibitors lack serine at the obligatory posi- 
tion for phosphorylation. 
as a competitive pseudosubstrate of CAMP-PK [23], were con- 
structed and are referred to as PKI-1 and PKI-2. These in- 
hibitors bind to and block the kinase substrate recognition site 
but do not themselves erve as substrates ince they lack the 
essential serine to be phosphorylated, and rather contain 
alanine at that site. Other compounds used as control peptides 
unable to act as such strong inhibitors of CAMP-PK included 
Kemptide, a synthetic substrate, and the peptide (Pro-Pro- 
Glyho. 
2.2. Hepatocyte isolation and culture 
Hepatocytes were prepared from adult male Sprague-Dawley 
rats (200-300 g) using a modification (241 of the collagenase 
perfusion method of Seglen [25]. Isolated cells (5 x 106) were 
cultured in 10 cm Falcon tissue culture dishes for 48 h at 37°C 
in Ham’s F-12 medium (Biochrom) containing 10% fetal calf 
serum (FCS), insulin (1 pg/ml), penicillin (100 U/ml) and strep- 
tomycin sulfate (100 /g/ml). Four hours prior to experiments, 
cells were changed to medium without FCS and insulin. There- 
after, cells were treated as described for individual experiments 
in the figure legends. In all experiments, inhibitors (either H8, 
PKI or Rp-CAMPS) were added to cells 30 min before 
stimulants were added for an additional 3 h. SCPT-CAMP was 
obtained from Boehringer, Kemptide and the peptide (Pro-Pro- 
Gly)io from Peninsula, and H8 from Dr Hugo De Jonge (Rot- 
terdam). Sp-CAMPS and Rp-CAMPS were synthesized in our 
laboratory (Jastorff, B.). PKI-1 and PKI-2 were synthesized by 
Dr Dieter Palm (Wilrzburg). 
2.3. Measurement of mRNA levels by Northern blot analysis 
Total cellular RNA was extracted using a LiCl-urea method 
[26], applied to agarose gels and transferred to nitrocellulose 
for Northern blot hybridization analysis as described [27,28]. 
The mRNA levels for TAT, PEPCK and albumin were 
measured by hybridization of “P-labeled complementary RNA 
transcripts made from SP6 plasmids containing the respective 
cDNAs as described [27,28]. Radioactively labeled mRNA was 
visualized by exposure of nitrocellulose blots to Kodak XAR-5 
film with intensifiers, and was quantitated by liquid scintillation 
counting of radioactive bands cut from the blots. 
3. RESULTS 
3.1. Inhibition of CAMP-stimulated mRNA levels 
by H8 
In preliminary experiments (not shown), the 
stimulation of mRNA for TAT in hepatocytes was 
observed to be maximal at 3 h of incubation with 
20 PM 8CPT-CAMP. 3 h incubations with 50 PM 
8CPT-CAMP were used for examining inhibitors 
of mRNA levels in the following experiments. A 
20-fold stimulation of mRNATAT levels above con- 
trol was observed in cells treated with 50pM 
CAMP and this was half maximally inhibited by 
40pM H8 (fig.2). This inhibitor concentration 
observed in intact cells appears reasonable con- 
sidering the reported in vitro Ki value of H8 for 
28 
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Fig.2. Northern blot (A), and its quantitation (B), of the mRNA 
level for TAT, PEPCK and albumin in hepatocytes in response 
to SCPT-CAMP, in the absence or presence of increasing con- 
centrations of H8. 
PKI-1 ha) 
CAMP-PK of 1.2 ,uM [22] and that which we 
observed (3.5 ,uM) using an in vitro protein kinase 
assay with purified C and Kemptide as substrate 
(not shown). 
The mRNA level of PEPCK, another CAMP- 
regulated enzyme in rat liver, was also analyzed 
and a similar inhibition by H8 as that observed for 
the mRNA of TAT was found (fig.2B). In con- 
trast, the level of mRNA for albumin, which is not 
regulated by CAMP, was unchanged by the treat- 
ment of hepatocytes with H8 (fig.2). 
3.2. Inhibition of CAMP-stimulated mRNA levels 
by PKI-1 and PKI-2 
PKI-1 corresponds to the 20-amino acid syn- 
thetic peptide described as having a Ki value of 
0.8 PM [29], and which we determined in our ex- 
periments to be 0.7 PM using an in vitro protein 
kinase assay with purified C and Kemptide as sub- 
strate (not shown). PKI-2 also contained 20 amino 
acids, but compared to PKI-1, its sequence started 
6 amino acids closer to the NHz-terminal end of 
the Walsh protein, and it had a reported Ki value 
of 0.3 nM, or 5 nM in our assay, as analyzed by 
Henderson plot analysis of tight-binding inhibitors 
[23]. lOOO-fold higher concentrations were re- 
quired for equal inhibition of cGMP-PK compared 
to CAMP-PK (not shown), which is consistent with 
other published data [30]. Concentrations between 
200,~M and 1 mM of both PKI-1 and PKI-2 in- 
hibited the CAMP-stimulated mRNA levels for 
MI-2 (mm) (Ra Ro*&ri (mm) 
r 
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Fig.3. Northern blot showing stimulation of mRNA levels for TAT and PEPCK by SCPT-CAMP and its dose-dependent inhibition 
by the active peptide fragments, PKI-1 and PKI-2 of the Walsh inhibitor. An equivalent concentration of another unspecific peptide 
(Pro-Pro-Gly)io was an ineffective inhibitor. PKI-1 and PKI-2 did not reduce the mRNA levels of albumin (not shown). 
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TAT and PEPCK, although the inhibition by 
PKI-2 was somewhat greater (fig.3). As with H8, 
these peptides had no effect on the mRNA level of 
albumin which is not CAMP regulated. Other pep- 
tides were studied to determine the specificity of 
the PKI inhibition. Kemptide, for example, a 
7-amino acid synthetic substrate of CAMP-PK 
(K, = 16 PM) was not a successful inhibitor of 
CAMP-stimulated mRNA levels for TAT or 
PEPCK (not shown). Another unrelated peptide of 
comparable molecular mass to PKI-1 and PKI-2, 
(Pro-Pro-Gly)io (fig.3) had little or no effect on 
these mRNA levels. The inhibition by PKI-1 and 
PKI-2 was dose dependent and was 80-90% com- 
plete at 1 mM PKI-2. The proposed mechanism of 
entry of PKI into hepatocytes, and the small frac- 
tion of the administered PKI which most likely 
reaches the intracellular protein kinase are con- 
sidered in section 4. 
3.3. Inhibition of CAMP-stimulated mRNA levels 
by Rp-CAMPS 
Whereas H8 and PKI are inhibitors of kinase 
catalytic activity, Rp-CAMPS is a cell permeable, 
competitive antagonist for CAMP binding to R of 
CAMP-PK, and R occupation by Rp-CAMPS 
prevents the dissociation of CAMP-PK [31]. Using 
the Kemptide assay and Sp-CAMPS stimulation of 
CAMP-PK, Rp-CAMPS was determined to have a 
Ki value of 5 PM in vitro (not shown). In intact 
hepatocytes in culture, 200pM Rp-CAMPS pro- 
duced nearly complete inhibition of the increase in 
mRNA for TAT (fig.4) or PEPCK (not shown) in 
response to 10 yM Sp-CAMPS. A residual level of 
WI-2ttmw: - - - - + + t + 
I1cPl-cAMP(sotdyI): - t - f - t - + 
LhqJM): - -t+--t+ 
TIT 
mRNA - 
Fig.5. Inhibition of both SCPT-CAMP and dexamethasone 
stimulated mRNA’*= levels by PKI-2. Stimulation by maximal 
doses of both 8CPT-CAMP and dexamethasone together (in the 
absence of PKI-2) were not additive. 
mRNA remained, however, similar to the level 
observed when Rp-CAMPS was present alone. 
Also shown in fig.4 is the stimulation of mRNA 
for TAT by dexamethasone which was not in- 
hibited by Rp-CAMPS. This lack of inhibition of 
dexamethasone’s effect by Rp-CAMPS has also 
been observed by others [28], and was in contrast 
to the inhibition of dexamethasone by H8 (not 
shown) and by PKI (see section 3.4). 
3.4. Stimulation of mRNATAr by dexamethasone 
and 8CPT-CAMP are not additive 
The question of whether dexamethasone and 
8CPT-CAMP influence the mRNA levels for TAT 
by completely separate mechanisms was in- 
vestigated. Maximal concentrations of both agents 
used together were not additive (fig.5), suggesting 
that some common element may be involved in 
both pathways of stimulation. PKI-2 inhibition of 
either agent alone, or in combination, was ob- 
served (fig.5). 
Fig.4. Northern blot analysis of the antagonism of Rp-CAMPS on the mRNA’*’ level stimulated by Q-CAMPS. Rp-CAMPS did not 
antagonize dexamethasone-stimulated levels. 
30 
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4. DISCUSSION 
Three inhibitors of CAMP-PK acting by dif- 
ferent mechanisms decreased the level of CAMP- 
stimulated mRNA for TAT and for PEPCK. H8 
and PKI inhibit the catalytic activity of C whereas 
Rp-CAMPS prevents the dissociation of the kinase 
holoenzyme and thereby the formation of the ac- 
tive free C. Results with all three inhibitors support 
the primary importance of CAMP-dependent pro- 
tein kinase activation in CAMP-regulated gene ex- 
pression. Furthermore the results obtained with 
H8 and PKI indicated that C-dependent phos- 
phorylation is clearly required for CAMP stimula- 
tion of mRNA levels. Although H8 can inhibit 
other protein kinases besides CAMP-PK [22], in 
the experimental setting being used here, such 
kinases would not contribute to the effects ob- 
served since they would not be CAMP stimulated. 
Additionally, PKI was tested since it is a specific 
peptide inhibitor containing an arginine cluster 
that mimics the well-established basic amino acid 
subsite that is the primary recognition site for sub- 
strates of CAMP-PK. Two lines of evidence in- 
dicated that the inhibition by PKI of mRNA levels 
for TAT and PEPCK was specific. First, mRNA 
levels for albumin were unchanged implying that 
PKI did not have a general deleterious effect on the 
cells. Second, other peptides of similar size did not 
inhibit the mRNA for TAT or PEPCK. High con- 
centrations of PKI were needed since it is expected 
that this size molecular mass peptide does not effi- 
ciently enter cells. However, it has been possible to 
introduce molecules as large as a monoclonal anti- 
body [32] and DNA [33] into cells that endocytose. 
Small amounts enter the cell, and a small fraction 
of that avoids digestion, and in the case of DNA 
can even eventually enter the nucleus and result in 
expression of new genes [33]. A recent preliminary 
report presented in abstract form [34] also in- 
dicated that intracellular expression of a minigene 
coding for a fragment of PKI could inhibit the ac- 
tivity of a fusion gene containing the CAMP- 
regulated promoter for enkephalin and the chlor- 
amphenicol acetyltransferase reporter gene. 
Both H8 and PKI were able to inhibit the dexa- 
methasone stimulation of TAT and PEPCK 
mRNA levels (not shown). It is possible that 
CAMP plays a permissive role in the effect of dexa- 
methasone on gene expression and that there is 
some intermediate factor common to both path- 
ways of stimulation. This was suggested by ex- 
periments in which the effects of 8CPT-CAMP and 
dexamethasone were shown not to be additive. 
Dexamethasone-stimulated mRNA levels were 
resistant to inhibition by Rp-CAMPS perhaps 
because this was not a strong enough inhibitor of 
cellular endogenous CAMP to totally block the per- 
missive effect of CAMP. Also, synthetic Rp- 
CAMPS itself had a certain basal stimulatory ac- 
tivity since it appeared not to be completely free of 
contamination by CAMP (see also [27]). This was 
particularly obvious in in vitro protein kinase 
assays. Alternatively, in intact cell experiments Rp- 
CAMPS may also elevate CAMP levels due to its 
ability to inhibit phosphodiesterase [21]. 
The data presented indicate that unlike the 
mechanism of CAMP-mediated gene expression in 
procaryotes and in a lower eucaryote, Dictyoste- 
lium discoideum, the mechanism in mammals re- 
quires C activity and a potential phosphoprotein 
intermediary factor. The proposed CAMP 
regulatory element consensus sequence suggested 
for several genes [ 11,12,35] thus most likely binds 
a protein whose phosphorylation is regulated by C. 
One such protein has been postulated to be a 
40 kDa nuclear protein [36]; functional studies will 
be needed to test this. Although R-II is also a pro- 
minent substrate for C subunit, our data (Btichler, 
W., Walter, U., Lohmann, S.M., Schmid, W. and 
Schlitz, G., unpublished) do not support a direct 
role for R-II as a DNA regulatory protein; no 
specific binding of either phospho- or dephospho- 
R-II to TAT promoter regions was detected. 
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